logo
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Independent6 days ago
Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy.
The highly unusual move is a latest in a string of events that have hammered the company's stock for weeks and recently forced it to lay off 500 employees. The company's decision not to comply with the FDA also places future availability of its leading therapy, called Elevidys, in doubt.
The FDA said in a statement Friday night that officials met with Sarepta and requested it suspend all sales but 'the company refused to do so.' The agency has the authority to pull drugs from the market, but the cumbersome regulatory process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply.
'We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges,' FDA Commissioner Marty Makary said in a statement.
Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects males, though it has faced scrutiny since its clearance in 2023. The one-time treatment received accelerated approval against the recommendations of some FDA scientists who doubted its effectiveness.
The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, including those who can no longer walk. Previously, it was only available for younger patients who were still walking.
Sarepta said Friday that its scientific review showed 'no new or changed safety signals' for younger patients with Duchenne's who have earlier stages of the disease. The company said it plans to keep the drug available for those patients.
'We look forward to continued discussions and sharing of information with FDA,' the company said in a statement.
Sarepta halted shipments last month of the therapy for older boys with Duchenne's, which gradually destroys muscle and skeletal strength, resulting in early death. The move followed the deaths of two teenage boys taking the therapy.
The company also confirmed a third death Friday: a 51-year-old patient who was taking an experimental gene therapy in a trial for a different form of muscular dystrophy. Sarepta said it reported the death to the FDA on June 20. The FDA said Friday it placed that trial on hold.
Sarepta noted that the gene therapy involved in the incident uses 'a different dose and is manufactured using a different process,' than Elevidys.
All three patient deaths were linked to liver injury, a side effect noted in Sarepta's prescribing information.
Earlier this week Sarepta announced it would add a bold warning to drug and lay off a third of its employees. The company did not mention the third patient death in its news release or conference call announcing those changes, sparking pointed criticism from Wall Street analysts.
Company shares fell more than 35% Friday to close at $14.07.
Cambridge, Massachusetts-based Sarepta has received FDA approval for three other Duchenne's drugs since 2016, none of which have been confirmed to work. The company has long been criticized for failing to complete several studies needed to secure full FDA approval of its drugs.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NFL star Joshua Hines-Allen reveals his seven-year-old son has been battling cancer
NFL star Joshua Hines-Allen reveals his seven-year-old son has been battling cancer

Daily Mail​

time27 minutes ago

  • Daily Mail​

NFL star Joshua Hines-Allen reveals his seven-year-old son has been battling cancer

Jacksonville Jaguars star Joshua Hines-Allen has revealed his seven-year-old son Wesley is nearly cancer free after battling leukemia for the past seven months. Hines-Allen, who did not travel to Indianapolis for the Jaguars' 2024 season finale in January due to personal reasons at the time, made the emotional announcement on social media along with his wife Kaitlyn. Kaitlyn recalled the initial concern they had when Wesley began bleeding from his tooth after a weekend at Disneyland. 'I was just hugging him 'cause he was crying and he started bleeding even more in the gums, then he started to catch a fever,' she explained. Joshua continued: 'It just didn't get better, and the bleeding was consistent every day.' The couple, who also have another son and daughter together, were then forced to take Wesley to hospital when his symptoms showed no signs of slowing down. The dreaded six-letter word that no parent ever wants to hear: Cancer. Seven months ago, our world stopped when our son, Wesley, was diagnosed with leukemia. As parents, we've held each other through tears we didn't know we had, watching our little boy fight the biggest battle… — Joshua Hines-Allen (@JoshHinesAllen) July 25, 2025 'I was just leaving practice,' Hines-Allen remembered. 'Kate called me [saying], "Hey, we're going to the hospital. I need you to go home and pack a bag for Wes." Not thinking anything of it, really. 'He wasn't feeling good at all still, so he's like cuddling up and we're waiting in the lobby to go back there. We finally get in the back, and then later that night [they] came back, pulled us out and they told us that he had leukemia. 'It just kind of like hit me, and nothing else mattered after that.' Doctors informed Joshua and Kaitlyn that Wesley's journey was going to be a long one, explaining how he will need to undergo regular testing for the next 21 years of his life aside from chemotherapy. Fortunately, Wesley has responded well to the treatment and is now nearing a full recovery, Kaitlyn revealed. He is set to undergo his final chemotherapy treatment in late August at Nemours Children's Health in Jacksonville. 'Wesley is doing great,' she said. 'He's swimming every day, he's running around, he's playing sports.' 'He's got back to being the big brother he is,' Joshua added. Along with the video and the encouraging update on Wesley's progress, Hines-Allen also announced that his foundation, Four One For All, is conducting a season-long campaign called Four One For Hope that aims to give back to four cancer-focused nonprofits throughout the 2025 campaign. 'We recently received the good news that Wesley is on his way to a full recovery,' he said in a separate statement, via ESPN. 'We are grateful to the dedicated team of doctors, nurses, and caretakers who contributed to our son's well-being and counseled us through this time. 'Our goal is to ensure that families going through something similar feel the same level of love and support as we did.' Hines-Allen is now gearing up for his seventh season with the Jaguars after being selected by the team with the seventh overall pick in the 2019 NFL Draft.

US court upholds California's implicit bias training mandate for doctors
US court upholds California's implicit bias training mandate for doctors

Reuters

time39 minutes ago

  • Reuters

US court upholds California's implicit bias training mandate for doctors

July 25 (Reuters) - A U.S. appeals court on Friday rejected claims that California violated the free speech rights of doctors who teach continuing medical education courses by mandating that they include information on implicit bias. A unanimous three-judge panel, opens new tab of the 9th U.S. Circuit Court of Appeals said that because the content of the courses, known as CMEs, is dictated by the state, it amounts to government speech shielded from constitutional scrutiny regardless of who delivers the message. The Medical Board of California requires physicians and surgeons to complete CMEs to maintain their licenses, and approves and accredits courses offered by doctors including Azadeh Khatibi, an ophthalmologist and the plaintiff in Friday's case. A 2021 state law requires that CMEs include information about implicit, or unconscious, bias and the potential for doctors to treat patients differently based on their race, sex or other factors. Khatibi and the nonprofit Do No Harm, which advocates against what it calls "radical, divisive and discriminatory ideologies" in the medical profession, say the law unlawfully forces instructors to endorse speech with which they may not agree in violation of the First Amendment of the U.S. Constitution. But the 9th Circuit said that speech belongs to the government, as it has more than a century of closely regulating the medical profession and adopting detailed requirements for CMEs. "If physicians are cognizant that their profession is heavily regulated [and] that they attend CMEs primarily to secure credits to maintain their licenses ... then 'common sense' commands that licensees could attribute approved CMEs' content to California," Circuit Judge Jacqueline Nguyen wrote. The panel included Circuit Judges A. Wallace Tashima and Salvador Mendoza. All three judges are appointees of Democratic presidents. Caleb Trotter of Pacific Legal Foundation, who represents Khatibi and Do No Harm, said the libertarian group was disappointed with the ruling and is considering its options. "If continuing medical education courses in California are 'government speech' as the panel decided today, then there is little to stop governments around the country from compelling continuing education instructors in any trade or profession to profess all manner of controversial state-endorsed topics," Trotter said in an emailed statement. Many states in recent years have conditioned professional licenses for doctors, lawyers, teachers and others on completing diversity or anti-racism training, prompting backlash from some professionals and conservative groups. A Michigan dentist represented by Pacific Legal filed a lawsuit, opens new tab in April over a state licensing requirement that healthcare providers complete implicit bias training. Last year, the St. Louis-based 8th Circuit rejected claims, opens new tab that a Missouri school district violated employees' free-speech rights by requiring them to attend anti-racism training. Friday's decision affirms a 2024 ruling by U.S. District Judge Monica Ramirez Almadani in Santa Ana, California, that dismissed the lawsuit by Khatibi and Do No Harm. The case is Khatibi v. Hawkins, 9th U.S. Circuit Court of Appeals, No. 24-3108. For Khatibi and Do No Harm: Joshua Thompson and Caleb Trotter of Pacific Legal Foundation For the state: Kristin Liska of the California Attorney General's office Read more: US court leery of free-speech challenge to school's anti-racism training U.S. law students to receive anti-bias training after ABA passes new rule

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store